CD8A and neoplasm: Topical administration of IL-7-Fc after HPV DNA vaccination increased the quantity of HPV-specific CD8+ T lymphocytes in the genital mucosa, resulting in a stronger anticancer immunity than HPV DNA vaccine alone. Mice cotreated with HPV vaccine and IL-7-Fc exhibited significantly attenuated tumor growth and promoted survival rate.